Paxlovid Tied to Benefits in High-Risk Patients With COVID

The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit.

Related Keywords

United Kingdom ,Canada ,Vancouver ,British Columbia ,Ohio ,United States ,British ,Colinr Dormuth , ,University Of British Columbia ,British Columbia Ministry Of Health ,Medscape Coronavirus Resource Center ,Coronavirus Resource ,Medscape Medical ,High Risk Patients ,Cleveland Clinic ,British Columbia Ministry ,Published October ,Covid 19 Treatment ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Inpatient Care ,Immunocompromise ,Immunocompromised ,Clinical Research ,Clinical Trials ,Linical Studies ,Hospitals ,Immunizations ,Vaccination ,Covid 19 Omicron Variant ,Ovid 19 Omicronb 1 529 Variant ,Ovid 19b 1 5 ,